Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 22:11 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableCompletedINTERVENTIONAL

Hydrogen-rich Water and Appetite in Obesity

ClinicalTrials.gov · NCT06722326 · Registry updated: 2025-01-20

Condition / research focus: Obesity
Sponsor: University of Novi Sad, Faculty of Sport and Physical Education
Countries with listed sites: Serbia
Registry dates and results: Start: 2024-05-15. Completion: 2024-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dietary Supplement: Hydrogen-rich water (dietary_supplement)
Dietary Supplement: Control water (dietary_supplement)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Applied Bioenergetics Lab
Novi Sad, Vojvodina, Serbia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

ClinicalTrials.gov · NCT03087032 · Registry updated: 2025-01-13

Condition / research focus: Type 2 Diabetes Patients; Overweight and Obesity; Hyperglycaemia (Diabetic)
Sponsor: The First Affiliated Hospital of Xiamen University
Countries with listed sites: China
Registry dates and results: Start: 2019-01-10. Completion: 2025-02-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victozaa, Liraglutid, Liroglutide, Liraglutidum, Liraglutide Acetate
insulin glargine (drug) — also listed as: Lantus

Where the study takes place — 1 listed sites

The first afilliated hospital of Xiamen university
Xiamen, Fujian, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Longitudinal Study of the GLUcagon REsponse to Hypoglycemia in Children and Adolescents With New-onset Type 1 DIAbetes

ClinicalTrials.gov · NCT06770621 · Registry updated: 2025-01-13

Condition / research focus: Severe Hypoglycemia; Type1diabetes
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Countries with listed sites: Belgium
Registry dates and results: Start: 2022-05-25. Completion: 2025-10-25 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin-induced hypoglycemia test (diagnostic_test)
Glucagon profile (diagnostic_test)
Biological sample once (other)
Observation-questionnaire (other)

Where the study takes place — 1 listed sites

Clinique Universitaires Saint Luc
Brussels, Woluwe-saint-lambert, Belgium
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Comparison of Diabetes Patients - Care Trajectory Versus Convention

ClinicalTrials.gov · NCT06577584 · Registry updated: 2025-01-10

Condition / research focus: Type 2 Diabetes
Sponsor: Universitaire Ziekenhuizen KU Leuven
Countries with listed sites: No country reported
Registry dates and results: Start: 2025-02-01. Completion: 2025-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Follow-up in the Diabetes Care Trajectory (other)
Follow-up in the Diabetes Convention (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

ClinicalTrials.gov · NCT05794581 · Registry updated: 2024-12-27

Condition / research focus: Type 1 Diabetes
Sponsor: Carmot Therapeutics, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2023-03-21. Completion: 2024-04-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

CT-868 (drug)
Placebo (drug)
Victoza (drug) — also listed as: Liraglutide

Where the study takes place — 1 listed sites

Carmot Clinical Research Unit 101
Chula Vista, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

ClinicalTrials.gov · NCT06361238 · Registry updated: 2024-12-20

Condition / research focus: Delirium, Postoperative
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Countries with listed sites: China
Registry dates and results: Start: 2024-11-19. Completion: 2028-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide injection (drug) — also listed as: Victoza
Placebo injection (drug) — also listed as: Normal saline

Where the study takes place — 1 listed sites

Wenxue liu
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Very Low Carbohydrate Diets and Glucagon Response in T1DM

ClinicalTrials.gov · NCT04200391 · Registry updated: 2024-12-18

Condition / research focus: Type1diabetes
Sponsor: Boston Children's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2020-01-03. Completion: 2026-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Very low carbohydrate diet (other)

Where the study takes place — 1 listed sites

Boston Children's Hospital
Boston, Massachusetts, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2 / Phase 3RecruitingINTERVENTIONAL

Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide

ClinicalTrials.gov · NCT06387199 · Registry updated: 2024-12-18

Condition / research focus: Type 1 Diabetes; Diabetes Mellitus
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Countries with listed sites: Canada
Registry dates and results: Start: 2024-12-01. Completion: 2027-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide with 4 meal strategies (drug)
Placebo with 4 meal strategies (drug)

Where the study takes place — 1 listed sites

Research Institute of the McGill University Health Centre
Montreal, Quebec, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1TerminatedINTERVENTIONAL

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

ClinicalTrials.gov · NCT05694741 · Registry updated: 2024-12-13

Condition / research focus: Type 2 Diabetes
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2022-12-20. Completion: 2023-05-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AZD0186 (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Research Site
Glendale, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

ClinicalTrials.gov · NCT05706506 · Registry updated: 2024-12-13

Condition / research focus: Type 2 Diabetes; Diabetes Mellitus, Type 2
Sponsor: Eli Lilly and Company
Countries with listed sites: United States
Registry dates and results: Start: 2023-03-08. Completion: 2023-10-31 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176

Where the study takes place — 32 listed sites

Fiel Family and Sports Medicine PC
Tempe, Arizona, United States
Site recruitment: Not reported
New Hope Research Development
Corona, California, United States
Site recruitment: Not reported
Velocity Clinical Research, Gardena
Gardena, California, United States
Site recruitment: Not reported
Velocity Clinical Research, Huntington Park
Huntington Park, California, United States
Site recruitment: Not reported
Velocity Clinical Research, Huntington Park
Los Angeles, California, United States
Site recruitment: Not reported
Valley Clinical Trials, Inc.
Northridge, California, United States
Site recruitment: Not reported
Dream Team Clinical Research
Pomona, California, United States
Site recruitment: Not reported
Scripps Whittier Diabetes Institute
San Diego, California, United States
Site recruitment: Not reported
Metabolic Institute of America
Tarzana, California, United States
Site recruitment: Not reported
CMR of Greater New Haven, LLC
Waterbury, Connecticut, United States
Site recruitment: Not reported
Velocity Clinical Research, Hallandale Beach
Hallandale, Florida, United States
Site recruitment: Not reported
East Coast Institute for Research, LLC
Jacksonville, Florida, United States
Site recruitment: Not reported
Florida Institute For Clinical Research, LLC
Orlando, Florida, United States
Site recruitment: Not reported
New Tampa Health
Tampa, Florida, United States
Site recruitment: Not reported
Georgia Clinical Research
Lawrenceville, Georgia, United States
Site recruitment: Not reported
Endocrine Research Solutions, Inc.
Roswell, Georgia, United States
Site recruitment: Not reported
Velocity Clinical Research, Valparaiso
Valparaiso, Indiana, United States
Site recruitment: Not reported
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
Site recruitment: Not reported
Cotton O'Neil Clinic
Topeka, Kansas, United States
Site recruitment: Not reported
Versailles Family Medicine
Versailles, Kentucky, United States
Site recruitment: Not reported
Endocrine and Metabolic Consultants
Rockville, Maryland, United States
Site recruitment: Not reported
Clinical Research Professionals
Chesterfield, Missouri, United States
Site recruitment: Not reported
Clinical Research of South Nevada
Las Vegas, Nevada, United States
Site recruitment: Not reported
Palm Research Center Tenaya
Las Vegas, Nevada, United States
Site recruitment: Not reported
Advanced Medical Research
Maumee, Ohio, United States
Site recruitment: Not reported
Conrad Clinical Research
Edmond, Oklahoma, United States
Site recruitment: Not reported
Mountain View Clinical Research, Inc.
Greenville, South Carolina, United States
Site recruitment: Not reported
Texas Diabetes & Endocrinology, P.A.
Austin, Texas, United States
Site recruitment: Not reported
North Texas Endocrine Center
Dallas, Texas, United States
Site recruitment: Not reported
Memorial City Endocrine Consultants
Houston, Texas, United States
Site recruitment: Not reported
Consano Clinical Research, LLC
Shavano Park, Texas, United States
Site recruitment: Not reported
ClinPoint Trials
Waxahachie, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableActive, not recruitingOBSERVATIONAL

Semaglutide and Physical Activity for Obesity and Multimorbidity

ClinicalTrials.gov · NCT06234111 · Registry updated: 2024-12-12

Condition / research focus: Obesity Morbid; Multimorbidity; Obesity
Sponsor: Hvidovre University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2024-02-20. Completion: 2026-11 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide 2.4 mg, total diet replacement, behavioural intervention (combination_product) — also listed as: Wegovy, Nupo, Dietary counseling

Where the study takes place — 1 listed sites

Copenhagen University Hospital, Hvidovre
Hvidovre, Capital Region, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Effect of Exogenous Glucagon-like Peptide 2 on Cholecystokinin-induced Gallbladder Emptying

ClinicalTrials.gov · NCT04651868 · Registry updated: 2024-12-09

Condition / research focus: Gallbladder
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2020-12-10. Completion: 2021-04-27 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-2 (other)
Placebo (other)
CCK (other)
Placebo (other)

Where the study takes place — 1 listed sites

Gentofte University Hospital
Hellerup, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans

ClinicalTrials.gov · NCT06333496 · Registry updated: 2024-12-05

Condition / research focus: Blood Sugar; High; Overweight and Obesity; Fat Burn; Obesity; Heart Health Markers
Sponsor: Alpine Biotech LLC
Countries with listed sites: United States
Registry dates and results: Start: 2024-01-02. Completion: 2024-05-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 Booster (GB) (dietary_supplement)

Where the study takes place — 1 listed sites

Alpine Bio
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

ClinicalTrials.gov · NCT05912621 · Registry updated: 2024-12-04

Condition / research focus: Obesity; Overweight and Obesity; Overweight
Sponsor: Stanford University
Countries with listed sites: United States
Registry dates and results: Start: 2023-11-09. Completion: 2029-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Mounjaro

Where the study takes place — 1 listed sites

Clinical and Translational Research Unit
Palo Alto, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Basal Plus GLP1-ra on Glycemic Variability in CKD

ClinicalTrials.gov · NCT05218915 · Registry updated: 2024-12-03

Condition / research focus: Diabetes Mellitus; Diabetic Kidney Disease
Sponsor: Elaine Chow
Countries with listed sites: Hong Kong
Registry dates and results: Start: 2022-01-28. Completion: 2024-10-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dulaglutide (drug)
Insulin Degludec (drug)
Continuous glucose monitor (device)

Where the study takes place — 1 listed sites

Prince of Wales Hospital
Shatin, Hong Kong
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

ClinicalTrials.gov · NCT03965130 · Registry updated: 2024-11-26

Condition / research focus: Healthy Participants
Sponsor: Yale University
Countries with listed sites: United States
Registry dates and results: Start: 2019-06-05. Completion: 2023-07-06 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon (biological) — also listed as: hormone study
Control Study (other) — also listed as: No glucagon

Where the study takes place — 1 listed sites

Yale Hospital reserach Unit / YCCI
New Haven, Connecticut, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy

ClinicalTrials.gov · NCT04883346 · Registry updated: 2024-11-20

Condition / research focus: Obesity; Status Post Sleeve Gastrectomy
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Countries with listed sites: United States
Registry dates and results: Start: 2021-06-21. Completion: 2024-04-30 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Saxenda

Where the study takes place — 1 listed sites

National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

High-amylose Barley (HIAMBA) in the Regulation and Prevention of Type 2 Diabetes

ClinicalTrials.gov · NCT04702672 · Registry updated: 2024-11-14

Condition / research focus: Type 2 Diabetes
Sponsor: University of Aarhus
Countries with listed sites: Denmark
Registry dates and results: Start: 2023-01-01. Completion: 2024-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

100% wheat (control) (dietary_supplement)
100% Lean-baking barley® (dietary_supplement)
100% regular barley (dietary_supplement)

Where the study takes place — 1 listed sites

Aarhus University Hospital
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4Not yet recruitingINTERVENTIONAL

Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention

ClinicalTrials.gov · NCT06682351 · Registry updated: 2024-11-12

Condition / research focus: Prediabetes / Type 2 Diabetes
Sponsor: Stanford University
Countries with listed sites: United States
Registry dates and results: Start: 2024-11. Completion: 2027-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Metformin (drug) — also listed as: MET
GLP-1A (drug) — also listed as: Glucagon-like peptide-1 analog
MED (dietary_supplement) — also listed as: Mediterranean Diet, energy-restricted Mediterranean diet

Where the study takes place — 1 listed sites

Stanford University
Stanford, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

ClinicalTrials.gov · NCT03555994 · Registry updated: 2024-11-12

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: MedImmune LLC
Countries with listed sites: Netherlands · Sweden · United Kingdom
Registry dates and results: Start: 2018-05-31. Completion: 2021-04-14 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

MEDI0382 (drug)
Placebo (drug)
Liraglutide (drug)

Where the study takes place — 3 listed sites

Research Site
Maastricht, Netherlands
Site recruitment: Not reported
Research Site
Uppsala, Sweden
Site recruitment: Not reported
Research Site
Nottingham, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 22:11 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableCompletedINTERVENTIONAL

Hydrogen-rich Water and Appetite in Obesity

ClinicalTrials.gov · NCT06722326 · Registry updated: 2025-01-20

Condition / research focus: Obesity
Sponsor: University of Novi Sad, Faculty of Sport and Physical Education
Countries with listed sites: Serbia
Registry dates and results: Start: 2024-05-15. Completion: 2024-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dietary Supplement: Hydrogen-rich water (dietary_supplement)
Dietary Supplement: Control water (dietary_supplement)

Where the study takes place — 1 listed sites

Applied Bioenergetics Lab
Novi Sad, Vojvodina, Serbia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

ClinicalTrials.gov · NCT03087032 · Registry updated: 2025-01-13

Condition / research focus: Type 2 Diabetes Patients; Overweight and Obesity; Hyperglycaemia (Diabetic)
Sponsor: The First Affiliated Hospital of Xiamen University
Countries with listed sites: China
Registry dates and results: Start: 2019-01-10. Completion: 2025-02-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victozaa, Liraglutid, Liroglutide, Liraglutidum, Liraglutide Acetate
insulin glargine (drug) — also listed as: Lantus

Where the study takes place — 1 listed sites

The first afilliated hospital of Xiamen university
Xiamen, Fujian, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Longitudinal Study of the GLUcagon REsponse to Hypoglycemia in Children and Adolescents With New-onset Type 1 DIAbetes

ClinicalTrials.gov · NCT06770621 · Registry updated: 2025-01-13

Condition / research focus: Severe Hypoglycemia; Type1diabetes
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Countries with listed sites: Belgium
Registry dates and results: Start: 2022-05-25. Completion: 2025-10-25 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin-induced hypoglycemia test (diagnostic_test)
Glucagon profile (diagnostic_test)
Biological sample once (other)
Observation-questionnaire (other)

Where the study takes place — 1 listed sites

Clinique Universitaires Saint Luc
Brussels, Woluwe-saint-lambert, Belgium
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Comparison of Diabetes Patients - Care Trajectory Versus Convention

ClinicalTrials.gov · NCT06577584 · Registry updated: 2025-01-10

Condition / research focus: Type 2 Diabetes
Sponsor: Universitaire Ziekenhuizen KU Leuven
Countries with listed sites: No country reported
Registry dates and results: Start: 2025-02-01. Completion: 2025-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Follow-up in the Diabetes Care Trajectory (other)
Follow-up in the Diabetes Convention (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

ClinicalTrials.gov · NCT05794581 · Registry updated: 2024-12-27

Condition / research focus: Type 1 Diabetes
Sponsor: Carmot Therapeutics, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2023-03-21. Completion: 2024-04-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

CT-868 (drug)
Placebo (drug)
Victoza (drug) — also listed as: Liraglutide

Where the study takes place — 1 listed sites

Carmot Clinical Research Unit 101
Chula Vista, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

ClinicalTrials.gov · NCT06361238 · Registry updated: 2024-12-20

Condition / research focus: Delirium, Postoperative
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Countries with listed sites: China
Registry dates and results: Start: 2024-11-19. Completion: 2028-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide injection (drug) — also listed as: Victoza
Placebo injection (drug) — also listed as: Normal saline

Where the study takes place — 1 listed sites

Wenxue liu
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Very Low Carbohydrate Diets and Glucagon Response in T1DM

ClinicalTrials.gov · NCT04200391 · Registry updated: 2024-12-18

Condition / research focus: Type1diabetes
Sponsor: Boston Children's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2020-01-03. Completion: 2026-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Very low carbohydrate diet (other)

Where the study takes place — 1 listed sites

Boston Children's Hospital
Boston, Massachusetts, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2 / Phase 3RecruitingINTERVENTIONAL

Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide

ClinicalTrials.gov · NCT06387199 · Registry updated: 2024-12-18

Condition / research focus: Type 1 Diabetes; Diabetes Mellitus
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Countries with listed sites: Canada
Registry dates and results: Start: 2024-12-01. Completion: 2027-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide with 4 meal strategies (drug)
Placebo with 4 meal strategies (drug)

Where the study takes place — 1 listed sites

Research Institute of the McGill University Health Centre
Montreal, Quebec, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1TerminatedINTERVENTIONAL

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

ClinicalTrials.gov · NCT05694741 · Registry updated: 2024-12-13

Condition / research focus: Type 2 Diabetes
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2022-12-20. Completion: 2023-05-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AZD0186 (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Research Site
Glendale, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

ClinicalTrials.gov · NCT05706506 · Registry updated: 2024-12-13

Condition / research focus: Type 2 Diabetes; Diabetes Mellitus, Type 2
Sponsor: Eli Lilly and Company
Countries with listed sites: United States
Registry dates and results: Start: 2023-03-08. Completion: 2023-10-31 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176

Where the study takes place — 32 listed sites

Fiel Family and Sports Medicine PC
Tempe, Arizona, United States
Site recruitment: Not reported
New Hope Research Development
Corona, California, United States
Site recruitment: Not reported
Velocity Clinical Research, Gardena
Gardena, California, United States
Site recruitment: Not reported
Velocity Clinical Research, Huntington Park
Huntington Park, California, United States
Site recruitment: Not reported
Velocity Clinical Research, Huntington Park
Los Angeles, California, United States
Site recruitment: Not reported
Valley Clinical Trials, Inc.
Northridge, California, United States
Site recruitment: Not reported
Dream Team Clinical Research
Pomona, California, United States
Site recruitment: Not reported
Scripps Whittier Diabetes Institute
San Diego, California, United States
Site recruitment: Not reported
Metabolic Institute of America
Tarzana, California, United States
Site recruitment: Not reported
CMR of Greater New Haven, LLC
Waterbury, Connecticut, United States
Site recruitment: Not reported
Velocity Clinical Research, Hallandale Beach
Hallandale, Florida, United States
Site recruitment: Not reported
East Coast Institute for Research, LLC
Jacksonville, Florida, United States
Site recruitment: Not reported
Florida Institute For Clinical Research, LLC
Orlando, Florida, United States
Site recruitment: Not reported
New Tampa Health
Tampa, Florida, United States
Site recruitment: Not reported
Georgia Clinical Research
Lawrenceville, Georgia, United States
Site recruitment: Not reported
Endocrine Research Solutions, Inc.
Roswell, Georgia, United States
Site recruitment: Not reported
Velocity Clinical Research, Valparaiso
Valparaiso, Indiana, United States
Site recruitment: Not reported
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
Site recruitment: Not reported
Cotton O'Neil Clinic
Topeka, Kansas, United States
Site recruitment: Not reported
Versailles Family Medicine
Versailles, Kentucky, United States
Site recruitment: Not reported
Endocrine and Metabolic Consultants
Rockville, Maryland, United States
Site recruitment: Not reported
Clinical Research Professionals
Chesterfield, Missouri, United States
Site recruitment: Not reported
Clinical Research of South Nevada
Las Vegas, Nevada, United States
Site recruitment: Not reported
Palm Research Center Tenaya
Las Vegas, Nevada, United States
Site recruitment: Not reported
Advanced Medical Research
Maumee, Ohio, United States
Site recruitment: Not reported
Conrad Clinical Research
Edmond, Oklahoma, United States
Site recruitment: Not reported
Mountain View Clinical Research, Inc.
Greenville, South Carolina, United States
Site recruitment: Not reported
Texas Diabetes & Endocrinology, P.A.
Austin, Texas, United States
Site recruitment: Not reported
North Texas Endocrine Center
Dallas, Texas, United States
Site recruitment: Not reported
Memorial City Endocrine Consultants
Houston, Texas, United States
Site recruitment: Not reported
Consano Clinical Research, LLC
Shavano Park, Texas, United States
Site recruitment: Not reported
ClinPoint Trials
Waxahachie, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableActive, not recruitingOBSERVATIONAL

Semaglutide and Physical Activity for Obesity and Multimorbidity

ClinicalTrials.gov · NCT06234111 · Registry updated: 2024-12-12

Condition / research focus: Obesity Morbid; Multimorbidity; Obesity
Sponsor: Hvidovre University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2024-02-20. Completion: 2026-11 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide 2.4 mg, total diet replacement, behavioural intervention (combination_product) — also listed as: Wegovy, Nupo, Dietary counseling

Where the study takes place — 1 listed sites

Copenhagen University Hospital, Hvidovre
Hvidovre, Capital Region, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Effect of Exogenous Glucagon-like Peptide 2 on Cholecystokinin-induced Gallbladder Emptying

ClinicalTrials.gov · NCT04651868 · Registry updated: 2024-12-09

Condition / research focus: Gallbladder
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2020-12-10. Completion: 2021-04-27 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-2 (other)
Placebo (other)
CCK (other)
Placebo (other)

Where the study takes place — 1 listed sites

Gentofte University Hospital
Hellerup, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans

ClinicalTrials.gov · NCT06333496 · Registry updated: 2024-12-05

Condition / research focus: Blood Sugar; High; Overweight and Obesity; Fat Burn; Obesity; Heart Health Markers
Sponsor: Alpine Biotech LLC
Countries with listed sites: United States
Registry dates and results: Start: 2024-01-02. Completion: 2024-05-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 Booster (GB) (dietary_supplement)

Where the study takes place — 1 listed sites

Alpine Bio
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

ClinicalTrials.gov · NCT05912621 · Registry updated: 2024-12-04

Condition / research focus: Obesity; Overweight and Obesity; Overweight
Sponsor: Stanford University
Countries with listed sites: United States
Registry dates and results: Start: 2023-11-09. Completion: 2029-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Mounjaro

Where the study takes place — 1 listed sites

Clinical and Translational Research Unit
Palo Alto, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Basal Plus GLP1-ra on Glycemic Variability in CKD

ClinicalTrials.gov · NCT05218915 · Registry updated: 2024-12-03

Condition / research focus: Diabetes Mellitus; Diabetic Kidney Disease
Sponsor: Elaine Chow
Countries with listed sites: Hong Kong
Registry dates and results: Start: 2022-01-28. Completion: 2024-10-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dulaglutide (drug)
Insulin Degludec (drug)
Continuous glucose monitor (device)

Where the study takes place — 1 listed sites

Prince of Wales Hospital
Shatin, Hong Kong
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

ClinicalTrials.gov · NCT03965130 · Registry updated: 2024-11-26

Condition / research focus: Healthy Participants
Sponsor: Yale University
Countries with listed sites: United States
Registry dates and results: Start: 2019-06-05. Completion: 2023-07-06 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon (biological) — also listed as: hormone study
Control Study (other) — also listed as: No glucagon

Where the study takes place — 1 listed sites

Yale Hospital reserach Unit / YCCI
New Haven, Connecticut, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy

ClinicalTrials.gov · NCT04883346 · Registry updated: 2024-11-20

Condition / research focus: Obesity; Status Post Sleeve Gastrectomy
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Countries with listed sites: United States
Registry dates and results: Start: 2021-06-21. Completion: 2024-04-30 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Saxenda

Where the study takes place — 1 listed sites

National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

High-amylose Barley (HIAMBA) in the Regulation and Prevention of Type 2 Diabetes

ClinicalTrials.gov · NCT04702672 · Registry updated: 2024-11-14

Condition / research focus: Type 2 Diabetes
Sponsor: University of Aarhus
Countries with listed sites: Denmark
Registry dates and results: Start: 2023-01-01. Completion: 2024-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

100% wheat (control) (dietary_supplement)
100% Lean-baking barley® (dietary_supplement)
100% regular barley (dietary_supplement)

Where the study takes place — 1 listed sites

Aarhus University Hospital
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4Not yet recruitingINTERVENTIONAL

Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention

ClinicalTrials.gov · NCT06682351 · Registry updated: 2024-11-12

Condition / research focus: Prediabetes / Type 2 Diabetes
Sponsor: Stanford University
Countries with listed sites: United States
Registry dates and results: Start: 2024-11. Completion: 2027-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Metformin (drug) — also listed as: MET
GLP-1A (drug) — also listed as: Glucagon-like peptide-1 analog
MED (dietary_supplement) — also listed as: Mediterranean Diet, energy-restricted Mediterranean diet

Where the study takes place — 1 listed sites

Stanford University
Stanford, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

ClinicalTrials.gov · NCT03555994 · Registry updated: 2024-11-12

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: MedImmune LLC
Countries with listed sites: Netherlands · Sweden · United Kingdom
Registry dates and results: Start: 2018-05-31. Completion: 2021-04-14 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

MEDI0382 (drug)
Placebo (drug)
Liraglutide (drug)

Where the study takes place — 3 listed sites

Research Site
Maastricht, Netherlands
Site recruitment: Not reported
Research Site
Uppsala, Sweden
Site recruitment: Not reported
Research Site
Nottingham, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →